Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of fostamatinib in rheumatoid arthritis
2008-000744-13Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fostamatinib in rheumatoid arthritis (RA), sponsored by AstraZeneca. Primary endpoint: Long-term safety of fostamatinib. Started Oct 2008; status: terminated.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-000744-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000744-13.